Processa Pharmaceuticals PCSA 深 沪
等待开盘 08-04 09:30:00 美东时间
0.2115
+0.001
+0.67%
华盛通- 最 高0.2179
- 今 开0.2092
- 成交量 410.59万股
- 最 低 0.203
- 昨 收 0.2101
- 总市值 554.01万
- 52周最高 1.58
- 市盈率 静 --
- 换手率 15.67%
- 52周最低 0.15
- 委 比 -99.90%
- 总股本 2619.44万
- 历史最高 284.80
- 量 比 1.29
- 振 幅 7.09%
- 历史最低 0.15
- 每 手 1
- 风险率 3.38%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Processa Pharmaceuticals Reschedules Annual Shareholder Meeting
Processa Pharmaceuticals ( ($PCSA) ) has provided an announcement. On June 30, ...
07-16 00:57
Processa Pharmaceuticals Provides Portfolio and Business Update
Processa Pharmaceuticals announced updates on their product pipeline, including a signed binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852, with potential milestone payments of up to $454 million. The company continues enrolling patients in the Phase 2 study of PCS6422 for metastatic breast cancer, expecting interim data in the second half of 2025. Processa also strengthened its balance sheet with a $7M capit...
07-01 13:00
美股大行评级 | 巨大分歧！Circle获多家大行首予评级目标价在80~250之间；Stifel上调甲骨文评级至"买入"，目标价升至250美元
美股大行评级 | 巨大分歧！Circle获多家大行首予评级目标价在80~250之间；Stifel上调甲骨文评级至"买入"，目标价升至250美元
07-01 09:24
HC Wainwright & Co. Maintains Buy on Processa Pharmaceuticals, Lowers Price Target to $2
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Processa Pharmaceuticals (NASDAQ:PCSA) with a Buy and lowers the price target from $6 to $2.
06-30 18:57
Processa Pharmaceuticals Analyst Ratings
Unity Software(U.US) reported fourth-quarter financial results after the market...
06-30 18:56
快讯 | Processa Pharmaceuticals, Inc. : H.c. Wainwright 将目标价从6美元下调至2美元
Processa Pharmaceuticals, Inc. : H.c. Wainwright Cuts Target Price to $2 From $6
06-30 18:08
Processa Pharmaceuticals Announces Licensing Deal with Intact
Processa Pharmaceuticals ( ($PCSA) ) has issued an update. On June 17, 2025, Pr...
06-17 22:57
Processa Pharmaceuticals (PCSA) Shares Soar 150% On Gastroparesis Drug Deal
Processa Pharmaceuticals' stock is surging after licensing a gastroparesis drug to Intact Therapeutics. The deal promises milestone payments and royalties for Processa.
06-17 22:17
Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering
Processa Pharmaceuticals announced a public offering of 28 million shares of common stock with warrants at $0.25 per share, expected to close on June 18, 2025. The gross proceeds of $7 million will fund Phase 2 trials for NCG-Cap and general corporate purposes. H.C. Wainwright & Co. is the placement agent, and the offering is subject to SEC registration.
06-17 16:26
Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate
Processa Pharmaceuticals和Intact Therapeutics达成协议，授予后者PCS12852的独家许可，用于治疗胃轻瘫和其他胃肠道疾病。Processa将获高达4.525亿美元里程碑付款、250万美元近期付款、未来销售的两位数 royalties，及Intact 3.5%股权。PCS12852在IIa期试验中表现优异，安全且有效，有望成为最佳治疗方案。双方合作旨在推进药物开发，满足临床需求。
06-17 13:00
